Curosurf (Poractant Alfa) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Curosurf (Poractant Alfa) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed during the historical period can be attributed to several factors, including increased demand for advanced medical solutions, the rising use of synthetic surfactants in hygiene products, greater healthcare awareness, improved access to healthcare, and an increased preference for easy-to-clean products, all of which have boosted synthetic surfactant sales.

Market growth during the forecast period can be attributed to factors such as the rising rates of premature births, the increasing use of synthetic surfactants in agrochemicals, the growing prevalence of chronic respiratory diseases, higher healthcare expenditure, and a greater preference for respiratory infection treatments. Key trends in the forecast period include the adoption of microdosing strategies, integration of surfactant therapy, increased use of biologic and immunomodulatory therapies, a shift toward sustainable and green surfactants, and a growing focus on neonatal and pediatric care.

The growing prevalence of respiratory disorders is expected to drive the curosurf (poractant alfa) market. Respiratory disorders, such as asthma, COPD, and lung cancer, lead to breathing difficulties and reduced lung function. Factors like increasing air pollution and an aging population, which contributes to a rise in age-related diseases like COPD, are contributing to the higher incidence of respiratory disorders. Poractant alfa plays a critical role in treating neonatal respiratory distress syndrome (NRDS) by improving lung function in premature infants. For example, in November 2023, the National Asthma Council reported 467 asthma-related deaths in Australia in 2022, an increase from the previous year, emphasizing the growing need for respiratory treatments like curosurf.

The rising prevalence of premature births is further boosting the demand for curosurf. Premature births, typically defined as births before 37 weeks of gestation, are increasingly common due to factors such as older maternal age and the widespread use of assisted reproductive technologies. Premature infants often develop respiratory distress syndrome, which is treated with poractant alfa to improve lung function and oxygen exchange. According to the Office for National Statistics, the premature live birth rate in England and Wales rose to 7.9% in 2022, up from 7.5% in 2021, indicating a steady increase in the number of premature births and further propelling the curosurf market.

A key trend in the curosurf market is the development of innovative treatments, such as novel inhaled gene therapy for respiratory disorders. This cutting-edge therapy involves delivering therapeutic genes directly to the lungs, offering new hope for conditions with limited treatment options. In November 2024, AlveoGene, a UK-based gene therapy developer, received Rare Pediatric Disease Designation from the FDA for AVG-002, a novel inhaled gene therapy targeting neonatal surfactant protein B (SP-B) deficiency, a genetic disorder leading to respiratory failure in infants. The gene therapy shows promise in preclinical studies, representing an innovative approach to treating respiratory conditions and further driving advancements in respiratory disorder management.

Key player operating in the curosurf (poractant alfa) market is Chiesi Farmaceutici, S.p.A.

North America was the largest region in the curosurf (poractant alfa) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in curosurf (poractant alfa) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the curosurf (poractant alfa) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Curosurf (poractant alfa) is a synthetic pulmonary surfactant primarily used for the treatment and prevention of respiratory distress syndrome (RDS) in preterm neonates. It is a synthetic version of pulmonary surfactant, a natural substance produced in the lungs that helps reduce surface tension and prevent the collapse of alveoli (small air sacs) in the lungs.

The primary types of curosurf (poractant alfa) are natural poractant alfa and synthetic poractant alfa. Natural poractant alfa is derived from animal lung extract, predominantly from porcine (pig) sources. Curosurf is distributed through various sales channels, including direct sales, distribution networks, and online marketplaces. It is used in the treatment of pulmonary edema, respiratory distress syndrome, and other respiratory disorders. Key end users include hospitals, clinics, and ambulance services.

The curosurf (poractant alfa) market research report is one of a series of new reports that provides curosurf (poractant alfa) market statistics, including curosurf (poractant alfa) industry global market size, regional shares, competitors with a curosurf (poractant alfa) market share, detailed curosurf (poractant alfa) market segments, market trends and opportunities, and any further data you may need to thrive in the curosurf (poractant alfa) industry. This curosurf (poractant alfa) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The curosurf (poractant alfa) market consists of sales of generic versions of poractant alfa, fostair, flemax, bricanils, and synthetic pulmonary surfactants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.